COVID does not hit the pause button on the needs of patients with liver cancer. GLI will continue to work with fellow advocates, medical societies, research agencies, local, state, and national governments to ensure that people living with liver cancer are not disproportionately impacted as important COVID-19 healthcare and public health strategies are implemented. Patients with life-threatening illnesses do not have the luxury of time.

This is why GLI is proud to announce the newly updated educational resource, The National Comprehensive Cancer Network (NCCN) Guidelines for Patients(R): Liver Cancer.  This resource is created from the NCCN evidence-based and expert consensus cancer treatment recommendations for healthcare professionals. These guidelines will play a vital role in helping patients navigate an expanding treatment field, and give them the tools to participate in decisions about their care. In 2018, GLI was thrilled to partner with NCCN and sponsor the first ever hepatobiliary guidelines for patients. We are pleased to continue serving as a sponsor of this valuable program that has grown to include two volumes addressing hepatobiliary cancers: the Liver Cancer brochure and Gallbladder and Bile Duct Cancers brochure. The Gallbladder and Bile Duct Cancers resource will be available in July 2020.

GLI President & CEO, Donna R. Cryer, JD, said, “In order to make the cancer journey more successful, GLI has partnered with the NCCN to update the NCCN Guidelines for Patients: Liver Cancer. The update includes new information on treatment options for liver cancer patients and their families. Together we can make a difference.” The NCCN Guidelines for Patients: Liver Cancer can be accessed for free online and print copies will be available soon through Amazon.com for a fee. Click here for online access.